Navigation Links
Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Date:10/23/2007

stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age- related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risks associated with regulatory processes, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, and for further pre-clinical and clinical studies, development and commercialization of product candidates. You are urged to consider statements that include the words "appear," "may," "will
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. Olympics of biotechnology has international flavor
3. Traffic data firm navigates international business
4. Catalyst International profit exceeds expectations
5. Lack of broadband hamstrings international videoconferencing
6. 30 days to success: Three simple steps to create your own international startup
7. TEKLYNX International announces new RFID software
8. Ruling enforces international trademark electronic filing requirements
9. Eleftheriou to lead Catalyst International
10. Internet trademark war goes international
11. International eyes drawn to Madisons games research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Nonalcoholic steatohepatitis,(NASH) ... approved,medical therapy for this chronic progressive liver disease. Researchers,tested ... program. To do so, 31 overweight or obese patients ...
... Oct. 27 Carna Biosciences, Inc. ("Carna"),announced on ... Agreement with,Shanghai Universal Biotech Company ("SUBC"). Under the ... distributor of Carna,s Protein,Kinases within China., With ... in,the life sciences, major biopharmaceutical companies have now ...
... BioAtom Inc. (private) announced,today that it will present ... 28, 2008 at 2:30 PM PDT (5:30 PM EDT) ... Myron Karasik, M.B.A., C.M.C., Director of Finance, will ... Costa Mesa, CA, dedicated,to development and commercialization of Neutron ...
Cached Biology Technology:Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... a celebrity living on mineral water, the glassy-winged sharpshooter ... in California, which is feverishly working to prevent the ... a surprising study published in the June 6 issue ... at The Institute for Genomic Research (TIGR), the University ...
... here have discovered a new mechanism used by cells ?and ... proteins, including some involved in cancer. , The mechanism ... made by the cell. , The study by researchers ... James Cancer Hospital and Richard J. Solove Research Institute and ...
... two frog species feared extinct has made a new ... save amphibians from a deadly fungus decimating their populations ... the two Critically Endangered frogs ?the Santa Marta harlequin ... (Atelopus nahumae) ?for the first time in 14 years ...
Cached Biology News:Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3Scientists discover new regulating mechanism in cells 2Scientists discover new regulating mechanism in cells 3Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 2Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 3
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
...
... 5 ml of DETACHaBEAD Mouse CD4, polyclonal ... T cells from Dynabeads Mouse CD4 (L3T4). ... cells from Dynabeads Mouse CD4 using DETACHaBEAD ... for any downstream application including flow cytometry, ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: